Current clinical and pharmacoeconomic aspects of osteoarthritis therapy

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Osteoarthritis is a disabling disease whose prevalence is constantly growing, resulting in an increasing economic burden on healthcare systems, including in Russia. The high cost of osteoarthritis therapy creates the preconditions for finding the most pharmacoeconomically optimal treatment options for this disease. This article analyzes existing clinical data on the efficacy and safety of the main osteoarthritis therapies, for which pharmacoeconomic studies have been conducted over the last ten years.

Толық мәтін

Рұқсат жабық

Авторлар туралы

S. Zyryanov

Peoples’ Friendship University of Russia named after Patrice Lumumba

Email: 1142221175@rudn.ru
ORCID iD: 0000-0002-6348-6867

Dr. Sci. (Med.), Professor, Head of the Department of General and Clinical Pharmacology

Ресей, Moscow

Anatoly Bondarev

Peoples’ Friendship University of Russia named after Patrice Lumumba

Хат алмасуға жауапты Автор.
Email: 1142221175@rudn.ru
ORCID iD: 0009-0009-5286-1463

Postgraduate Student, Department of General and Clinical Pharmacology

Ресей, Moscow

Әдебиет тізімі

  1. Hunter D.J., Bierma-Zeinstra S. Osteoarthritis. Lancet. 2019;393(10182):1745–1759. https://dx.doi.org/10.1016/S0140-6736(19)30417-9
  2. Katz J.N., Arant K.R., Loeser R.F. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA. 2021;325(6):568–578. https://dx.doi.org/10.1001/jama.2020.22171
  3. Kim Y.S., Guilak F. Engineering hyaluronic acid for the development of new treatment strategies for osteoarthritis. Int J Mol Sci. 2022;23(15):8662. https://dx.doi.org/10.3390/ijms23158662
  4. Chavda S., Rabbani S.A., Wadhwa T. Role and effectiveness of intra-articular injection of hyaluronic acid in the treatment of knee osteoarthritis: a systematic review. Cureus. 2022;14(4):e24503. https://dx.doi.org/10.7759/cureus.24503
  5. Long H., Liu Q., Yin H., et al. Prevalence trends of site-specific osteoarthritis from 1990 to 2019: findings from the Global Burden of Disease Study 2019. Arthritis Rheumatol. 2022;74:1172–1183. https://dx.doi.org/10.1002/art.42089
  6. Migliore A., Gigliucci G., Alekseeva L., et al. Systematic literature review and expert opinion for the use of viscosupplementation with hyaluronic acid in different localizations of osteoarthritis. Orthop Res Rev. 2021;13:255–273. https://dx.doi.org/10.2147/ORR.S336185
  7. Teitel A.D., Zieve D. MedlinePlud Medical Encycolpedia. National Institutes of Health. ‘Osteoarthritis.’ Last updated: Sept 26, 2011. Available at: http://www.nlm.nih.gov/medlineplus/ency/article/000423.htm. Accessed June 29, 2021.
  8. World Health Organization; 2016. Available at: http://www.who.int/chp/topics/rheumatic/en/. Accessed February 5, 2016.
  9. Naja M., Fernandez De Grado G., Favreau H., et al. Comparative effectiveness of nonsurgical interventions in the treatment of patients with knee osteoarthritis: A PRISMA-compliant systematic review and network meta-analysis. Medicine (Baltimore). 2021;100(49):e28067. https://dx.doi.org/10.1097/MD.0000000000028067
  10. Sakalauskiene G., Jauniskiene D. Osteoarthritis: etiology, epidemiology, impact on the individual and society and the main principles ofmanagement. Medicina (Kaunas) 2010;46:790–797.
  11. Anderson A.S., Loeser R.F. Why is osteoarthritis an age-related disease? Best Pract Res Clin Rheumatol 2010;24:15–26. https://dx.doi.org/10.1016/j.berh.2009.08.006
  12. Webner D., Huang Y., Hummer C.D. 3rd. Intraarticular hyaluronic acid preparations for knee osteoarthritis: are some better than others? Cartilage. 2021;13(1_suppl):1619S-1636S. https://dx.doi.org/10.1177/19476035211017320
  13. Балабанова Р.М., Дубинина Т.В. Динамика пятилетней заболеваемости болезнями костно-мышечной системы и их распространенности среди взрослого населения России за 2013–2017 гг. Современная ревматология. 2019;13(4):11–17. [Balabanova R.M., Dubinina T.V. Five-year (2013–2017) trends in the incidence and prevalence of musculoskeletal system diseases among the adult population of Russia. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(4):11–17. (In Russ.)]. https://dx.doi.org/10.14412/1996-7012-2019-4-11-17
  14. Наумов А.В., Воробьева Н.М., Ховасова Н.О. и др. Распространенность остеоартрита и его ассоциации с гериатрическими синдромами у лиц старше 65 лет: данные российского эпидемиологического исследования ЭВКАЛИПТ. Терапевтический архив. 2021;93(12):1482–1490. [Naumov A.V., Vorobyeva N.M., Khovasova N.O., et al. The prevalence of osteoarthritis and its association with geriatric syndromes in people over 65: data from the Russian epidemiological study EVKALIPT. Terapevticheskii Arkhiv. 2021;93(12):1482–1490. (In Russ.)]. https://dx.doi.org/10.26442/00403660.2021.12.201268
  15. Cohen E., Lee Y.C. A mechanism-based approach to the management of osteoarthritis pain. Curr Osteoporos Rep. 2015;13(6):399–406. https://dx.doi.org/10.1007/s11914-015-0291-y
  16. Krebs E.E., Gravely A., Nugent S., et al. Effect of opioid vs nonopioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain: the SPACE randomized clinical trial. JAMA. 2018;319:872–882. https://dx.doi.org/10.1001/jama.2018.0899
  17. Clausen S., Heerey J., Hartvigsen J., et al. Do imaging findings modify the effect of non-surgical treatment in patients with knee and hip osteoarthritis? A systematic literature review. BMJ Open. 2023;13(3):e065373. https://dx.doi.org/10.1136/bmjopen-2022-065373
  18. Sharma L. Osteoarthritis of the Knee. N Engl J Med. 2021;384:51–59. https://dx.doi.org/10.1056/NEJMcp1903768
  19. Mao B., Pan Y., Zhang Z., et al. Efficacy and safety of hyaluronic acid intra-articular injection after arthroscopic knee surgery: a systematic review and meta-analysis. Orthop Surg. 2023;15(1):16-27. https://dx.doi.org/10.1111/os.13602
  20. Singh H., Knapik D.M., Polce E.M., et al. Relative efficacy of intra-articular injections in the treatment of knee osteoarthritis: a systematic review and network meta-analysis. Am J Sports Med. 2022;52:3140–3148. https://dx.doi.org/10.1177/03635465211029659
  21. Nie F., Li W. Impact of prior intra-articular injections on the risk of prosthetic joint infection following total joint arthroplasty: a systematic review and meta-analysis. Front Surg. 2021;8:737529. https://dx.doi.org/10.3389/fsurg.2021.737529
  22. Abramoff B., Caldera F.E. Osteoarthritis: pathology, diagnosis, and treatment options. Med Clin North Am. 2020;104:293–311. https://dx.doi.org/10.1016/j.mcna.2019.10.007
  23. Aresti N., Kassam J., Nicholas N., et al. Hip osteoarthritis. BMJ (Clinical Research Ed) 2016;354:i3405. https://dx.doi.org/10.1136/bmj.i3405
  24. Ferrara P.E., Codazza S., Coraci D., et al. State of art in intra-articular hip injections of different medications for osteoarthritis: a systematic review. BMC Musculoskelet Disord. 2021;22(Suppl 2):997. https://dx.doi.org/10.1186/s12891-021-04866-6
  25. Nelson A.E., Allen K.D., Golightly Y.M., et al. A systematic review of recommendations and guidelines for the management of osteoarthritis: the chronic osteoarthritis management initiative of the U.S. Semin Arthritis Rheum. 2014;43:701–712. https://dx.doi.org/10.1016/j.semarthrit.2013.11.012
  26. Goh S.L., Persson M.S.M., Stocks J., et al. Relative efficacy of different exercises for pain, function, performance and quality of life in knee and hip osteoarthritis: systematic review and network meta-analysis. Sports Med. 2019;49:743–761. https://dx.doi.org/10.1007/s40279-019-01082-0
  27. Block J.A. Osteoarthritis: OA guidelines: improving care or merely codifying practice? Nat Rev Rheumatol. 2014;10:324–326. https://dx.doi.org/10.1038/nrrheum.2014.61
  28. Stott A. Hyaluronic acid and other conservative treatment options for osteoarthritis of the ankle. Orthop Nurs. 2017;36(5):361–362. https://dx.doi.org/10.1097/NOR.0000000000000384
  29. Costa B.R., Pereira T.V., Saadat P., et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ (Clinical Research Ed). 2021;375: n2321. https://dx.doi.org/10.1136/bmj.n2321
  30. Jones I.A., Togashi R., Wilson M.L., et al. Intra-articular treatment options for knee osteoarthritis. Nat Rev Rheumatol. 2019;15:77–90. https://dx.doi.org/10.1038/s41584-018-0123-4
  31. Arden N.K., Perry T.A., Bannuru R.R., et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021;17:59–66. https://dx.doi.org/10.1038/s41584-020-00523-9
  32. Wu Y.Z., Huang H.T., Ho C.J., et al. Molecular weight of hyaluronic acid has major influence on its efficacy and safety for viscosupplementation in hip osteoarthritis: a systematic review and meta-analysis. Cartilage. 2021;13(1_suppl):169S-184S. https://dx.doi.org/10.1177/19476035211021903
  33. Gibofsky A., Hochberg M.C., Jaros M.J., Young C.L. Efficacy and safety of low-dose submicron diclofenac for the treatment of osteoarthritis pain: a 12 week, phase 3 study. Curr Med Res Opin. 2014;30(9):1883–1893. https://dx.doi.org/10.1185/03007995.2014.946123
  34. Solomon D.H. NSAIDs: Pharmacology and mechanism of action. UpToDate. – 2021.
  35. Varas-Lorenzo C., Riera-Guardia N., Calingaert B., et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013;22(6):559–570. https://dx.doi.org/10.1002/pds.3437
  36. Coxib and traditional NSAID Trialists’ (CNT) Collaboration; Bhala N., Emberson J., Merhi A., et al. Coxib and traditional NSAID Trialists’(CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779. https://dx.doi.org/10.1016/S0140-6736(13)60900-9
  37. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet. 2005;365(9458):475–481. https://dx.doi.org/10.1016/S0140-6736(05)17864-7
  38. Schmidt M., Christiansen C.F., Mehnert F., et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: population based case-control study. BMJ. 2011;343:d3450. https://dx.doi.org/10.1136/bmj.d3450
  39. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5):13S–24S. https://dx.doi.org/10.1016/s0002-9343(99)00113-8
  40. Brater D.C. Anti-inflammatory agents and renal function. Semin Arthritis Rheum. 2002;32(3):33–42. https://dx.doi.org/10.1053/sarh.2002.37216
  41. Имаметдинова Г.Р., Чичасова Н.В. Хондроитина сульфат при заболеваниях опорно-двигательного аппарата: эффективность и безопасность с позиций доказательной медицины. Русский медицинский журнал. 2016;24(22):1481–1488. [Imametdinova G.R., Chichasova N.V. Chondroitin sulfate in diseases of the musculoskeletal system: efficacy and safety from the standpoint of evidence-based medicine. Rus Med J. 2016;24(22):1481–1488. (In Russ.)].
  42. Шавловская О.А. Хондропротекторы: спектр применения в общесоматической практике. Терапевтический архив. 2017;89(5): 98–104. [Shavlovskaya O.A. Chondroprotectors: A range of application in general somatic practice. Therapeutic Archive. 2017;89(5):98–104. (In Russ.)]. https://dx.doi.org/10.17116/terarkh201789598-104
  43. Reginster J.Y., Cooper C., Hochberg M., et al. Comments on the discordant recommendations for the use of symptomatic slow-acting drugs in knee osteoarthritis. Curr Med Res Opin. 2015;31(5):1041–1045. https://dx.doi.org/10.1185/03007995.2015.1027183
  44. Bruyère O., Cooper C., Pelletier J.P., et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis–from evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016;45(4):S3–S11. https://dx.doi.org/10.1016/j.semarthrit.2015.11.010
  45. Bourgeois P., Chales G., Dehais J., et al. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3×400 mg/day vs placebo. Osteoarthritis Cartilage.1998;6(Suppl A):25–30. https://dx.doi.org/10.1016/s1063-4584(98)80008-3
  46. Volpi N. Oral absorption and bioavailability of ichthyic origin chondroitin sulfate in healthy male volunteers. Osteoarthritis Cartilage. 2003;11(6):433–441. https://dx.doi.org/10.1016/s1063-4584(03)00051-7
  47. Bucsi L., Poór G. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage. 1998;6(Suppl A):31–36. https://dx.doi.org/10.1016/s1063-4584(98)80009-5
  48. Bellamy N. Osteoarthritis clinical trials: candidate variables and clinimetric properties. J Rheumatol. 1997;24(4):768–778.
  49. Jin X., Jones G., Cicuttini F., et al. Effect of vitamin D supplementation on tibial cartilage volume and knee pain among patients with symptomatic knee osteoarthritis: a randomized clinical trial. JAMA. 2016;315(10):1005–1013. https://dx.doi.org/10.1001/jama.2016.1961
  50. Pavelka K., Coste P., Géher P., Krejci G. Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clin Rheumatol. 2010;29:659–670. https://dx.doi.org/10.1007/s10067-010-1384-8.
  51. Pers Y.M., Rackwitz L., Ferreira R., et al. Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase I dose-escalation trial. Stem Cells Transl Med. 2016;5(7):847–856. https://dx.doi.org/10.5966/sctm.2015-0245
  52. Hochberg M.C., Altman R.D., Brandt K.D., et al. Guidelines for the medical management of osteoarthritis. Part II. Osteoarthritis of the knee. American College of Rheumatology. Arthritis Rheum. 1995;38(11):1541–1546. https://dx.doi.org/10.1002/art.1780381104
  53. Raynauld J.P., Buckland-Wright C., Ward R., et al. Safety and efficacy of long‐term intraarticular steroid injections in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2003;48(2):370–377. https://dx.doi.org/10.1002/art.10777
  54. de Campos G.C., Rezende M.U., Pailo A.F., et al. Adding triamcinolone improves viscosupplementation: a randomized clinical trial. Clin Orthop Relat Res. 2013;471(2):613–620. https://dx.doi.org/10.1007/s11999-012-2659-y
  55. Webb D., Naidoo P. Viscosupplementation for knee osteoarthritis: a focus on Hylan GF 20. Orthop Res Rev. 2018;10:73–81. https://dx.doi.org/10.2147/ORR.S174649
  56. Дроздов В.Н., Ших Е.В., Сереброва С.Ю. и др. Алфлутоп в современной симптом-модифицирующей терапии остеоартрита. Терапевтический архив. 2019;91(5):134–140. [Drozdov V.N., Shikh E.V., Serebrova S.Y., et al. Alflutop – in modern symptom-modifying osteoarthritis therapy. Therapeutic Archive. 2019;91(5):134–140. (In Russ.)]. https://dx.doi.org/10.26442/00403660.2019.05.000169
  57. Назарук А.М., Мех В.Н., Жук В.В. Опыт применения карбокситерапии в лечении заболеваний суставов и позвоночника. Сб. Медицинская реабилитация и санаторно-курортное лечение. 2017. С. 142–145. [Nazaruk A.M., Mekh V.N., Zhuk V.V. Experience of using carboxytherapy in the treatment of joint and spine diseases. Collection of articles: Medical rehabilitation and spa treatment. 2017. P. 142–145. (In Russ.)].
  58. Seredynska N.M., Drogovoz S.M., Shchokina E.G., et al. Analgesic action of invasive carboxytherapy: mechanisms and applications. Neurophysiology. 2021;53:56–64. Https://dx.doi.org/10.1007/s11062-021-09913-5
  59. Derwich M., Mitus-Kenig M., Pawlowska E. Mechanisms of action and efficacy of hyaluronic acid, corticosteroids and platelet-rich plasma in the treatment of temporomandibular jointoOsteoarthritis-a systematic review. Int J Mol Sci. 2021;22(14):7405. https://dx.doi.org/10.3390/ijms22147405
  60. Bowden D.J., Byrne C.A., Alkhayat A., et al. Injectable viscoelastic supplements: A review for radiologists. Am. J. Roentgenol. 2017;209(4):883–888. https://dx.doi.org/10.2214/AJR.17.17847
  61. Pavone V., Vescio A., Turchetta M., et al. Injection-based management of osteoarthritis of the knee: a systematic review ofgGuidelines. Front Pharmacol. 2021;12:661805. https://dx.doi.org/10.3389/fphar.2021.661805
  62. Peck J., Slovek A., Miro P., et al. A comprehensive review of viscosupplementation in osteoarthritis of the knee. Orthop. Rev. (Pavia). 2021;13(2):25549. (In Eng.) https://dx.doi.org/10.52965/001c.25549
  63. Glinkowski W.M., et al. Intra-Articular Hyaluronic Acid for Knee Osteoarthritis. J. Clin. Med. 2025;14(4):1272. (In Eng.) https://dx.doi.org/10.3390/jcm14041272
  64. Стребкова Е.А., Алексеева Л.И. Эффективность внутрисуставной терапии препаратами гиалуроновой кислоты у больных остеоартритом. Современная ревматология. 2019;13(2):96–104. [Strebkova E.A., Alekseeva L.I. Efficiency of intra-articular hyaluronic acid therapy in patients with osteoarthritis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(2):96–104. (In Russ.)]. https://dx.doi.org/10.14412/1996-7012-2019-2-96-104
  65. Yagishita K., Sekiya I., Sakaguchi Y., et al. The effect of hyaluronan on tendon healing in rabbits. Arthrosc J Arthrosc Relat Surg. 2005;21(11):1330–1336. doi: 10.1016/j.arthro.2005.08.020
  66. Altman R., Hackel J., Niazi F., et al. Efficacy and safety of repeated courses of hyaluronic acid injections for knee osteoarthritis: A systematic review. Semin Arthritis Rheum. 2018;48(2):168–175. https://dx.doi.org/10.1016/j.semarthrit.2018.01.009
  67. Leighton R., Akermark C., Therrien R., et al.; DUROLANE Study Group. NASHA hyaluronic acid vs. methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014;22(1):17-25. https://dx.doi.org/10.1016/j.joca.2013.10.009
  68. Bannuru R.R., Vaysbrot E.E., Sullivan M.C., McAlindon T.E. Relative efficacy of hyaluronic acid in comparison with NSAIDs for knee osteoarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;43(5):593–599. https://dx.doi.org/10.1016/j.semarthrit.2013.10.002
  69. Ozturk C., Atamaz F., Hepguler S., et al. The safety and efficacy of intraarticular hyaluronan with/without corticosteroid in knee osteoarthritis: 1-year, single-blind, randomized study. Rheumatol Int. 2006;26(4):314–319. https://dx.doi.org/10.1007/s00296-005-0584-z
  70. Алексеева Л.И., Кашеварова Н.Г., Таскина Е.А. и др. Эффективность и безопасность внутрисуставного применения комбинации гиалуроната натрия и хондроитина сульфата при остеоартрите коленного сустава: многоцентровое проспективное исследование. Терапевтический архив. 2020;92(5):46–54. [Alekseeva L.I., Kashevarova N.G., Taskina E.A., et al. The efficacy and safety of intra-articular application of a combination of sodium hyaluronate and chondroitin sulfate for osteoarthritis of the knee: a multicenter prospective study. Therapeutic Archive. 2020;92(5):46–54. (In Russ.)]. https://dx.doi.org/10.26442/00403660.2020.05.000631
  71. Jin X., Liang W., Zhang L., et al. Economic and humanistic burden of osteoarthritis: an updated systematic review of large sample studies. PharmacoEconomics. 2023;41(11):1453–1467. https://dx.doi.org/10.1007/s40273-023-01296-1
  72. Reginster J.Y., Veronese N. Highly purified chondroitin sulfate: a literature review on clinical efficacy and pharmacoeconomic aspects in osteoarthritis treatment. Aging Clin Exp Res. 2021;33(1):37–47. https://dx.doi.org/10.1007/s40520-020-01643-8
  73. Денисов Л.Н., Алексеева Л.И., Зоткин Е.Г. и др. Терапия остеоартрита коленных суставов с точки зрения доказательной медицины: ожидаемые краткосрочные, среднесрочные и долгосрочные результаты применения рецептурного кристаллического глюкозамина сульфата. Современная ревматология. 2022;16(4):80–87. [Denisov L.N., Alekseeva L.I., Zotkin E.G., et al. Evidence-based therapy for knee osteoarthritis: expected short-, medium-, and longterm outcomes of prescription crystalline glucosamine sulfate administration. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022;16(4):80–87. (In Russ.)]. https://dx.doi.org/10.14412/1996-7012-2022-4-80-87
  74. Давлатзода А.Д., Саидов Ё.У., Махмудов Х.Р., Джамолова Р.Д. Сравнительный клинико-фармакоэкономический анализ и оценка эффективности комплексной терапии у больных первичным остеоартритом коленных суставов I–III стадий, основанные на современной терапевтической стратегии. Bестник Авиценны. 2021;23(4):520–531. [Davlatzoda A.D., Saidov Yo.U., Makhmudov Kh.R., Jamolova R.J. Comparative clinical and pharmacoeconomic analysis of the efficacy of modern combination therapy in patients with primary knee osteoarthritis, stages I–III. Vestnik Avitsenny [Avicenna Bulletin]. 2021;23(4):520–531. (In Russ.)]. https://doi.org/10.25005/2074-0581-2021-23-4-520-531
  75. Цветкова Е.С., Белоусов Д.Ю., Афанасьева Е.В. Фармакоэкономический анализ применения препарата Мовалис у больных с остеоартрозом и ревматоидным артритом. Качественная клиническая практика. 2015;1:66–76. [Tsvetkova E.S., Belousov D.Yu., Afanasyeva E.V. Pharmacoeconomic analysis of the use of Movalis in patients with osteoarthritis and rheumatoid arthritis. Qualitative Clinical Practice. 2015;1:66-76. (In Russ.)].
  76. Двойникова О.О., Зейналова Э.К.К., Минакова Н.И. и др. Фармакоэкономический анализ использования НПВС у пациентов с остеоартритом умеренной степени тяжести. Наукосфера. 2022;7(1):27–31. [Dvoynikova O.O., Zeynalova E.K.K., Minakova N.I., et al. Pharmacoeconomic analysis of the use of NSAIDs in patients with moderate osteoarthritis. Naukosphere. 2022;7(1):27–31. (In Russ.)].
  77. Насонова В.А., Воробьев П.А., Цветкова Е.С., Авксентьева М.В. Фармакоэкономический анализ применения двух нестероидных противовоспалительных препаратов в ревматологии. Научно-практическая ревматология. 2002;1:63–68. [Nasonova V.A., Vorobyov P.A., Tsvetkova E.S., Avksentyeva M.V. Pharmacoeconomic analysis of the use of two non-steroidal anti-inflammatory drugs in rheumatology. Scientific and Practical Rheumatology. 2002;1:63–68. (In Russ.)].
  78. Андрияшкина Д.Ю., Клименко А.А., Демидова Н.А. и др. Препараты замедленного действия для лечения остеоартрита коленных суставов – препараты выбора у коморбидного пациента. Фарматека. 2023;1–2:182–187. [Andriyashkina D.Yu., Klimenko A.A., Demidova N.A., et al. Symptomatic slow-acting drugs in the treatment of knee osteoarthritis: the drugs of choice in comorbid patients. Farmateka. 2023;1–2:182–187. (In Russ.)]. https://dx.doi.org/10.18565/pharmateca.2023.1-2.182-187
  79. Майко О.Ю. Фармакоэкономические аспекты применения хондроитина сульфата у больных остеоартрозом в амбулаторных условиях. Проблемы стандартизации в здравоохранении. 2020;3–4:72–77. [Maiko O.Yu. Pharmacoeconomic aspects of using chondroitin sulfate in the outpatient treatment of patients with osteoarthritis. Health Care Standardization Problems. 2020;3–4:72–77. (In Russ.)]. https://dx.doi.org/10.26347/1607-2502202003-04072-077
  80. Каплунов О.А., Каплунов К.О. Клинические случаи применения SYSADOA в комплексной консервативной терапии пациента с остеоартритом коленного сустава. Лечащий врач. 2021;7(24):49–52. [Kaplunov O.А., Kaplunov K.О. Clinical cases of SYSADOA use in complex conservative therapy of patients with knee osteoarthritis. Lechaschy Vrach. 2021;7(24):49–52. (In Russ.)]. https://dx.doi.org/10.51793/OS.2021.24.7.009
  81. Крысанов И.С., Крысанова В.С., Ермакова В.Ю. Фармакоэкономический анализ применения симптом-модифицирующих препаратов замедленного действия в лечении остеоартрита. Фармакология & Фармакотерапия. 2022;2:52–59. [Krysanov I.S., Krysanova V.S., Ermakova V.Yu. Pharmacoeconomic analysis of the use of symptom-modifying slow-release drugs in the treatment of osteoarthritis. Pharmacology & Pharmacotherapy. 2022;2:52–59. (In Russ.)].
  82. Измалков С.Н., Братийчук А.Н., Хмелевских О.В. Клиническая и фармакоэкономическая эффектиность карбокситерапии у больных гонартрозом II стадии. Сб. Вопросы управления в развитии системы первичной медико-санитарной помощи: актуальные вопросы гематологии. 2017;150–153. [Izmalkov S.N., Bratiychuk A.N., Khmelevskikh O.V. Clinical and pharmacoeconomic effectiveness of carboxytherapy in patients with stage II gonarthrosis. Collection of scientific papers. Management issues in the development of the primary health care system: current issues in hematology. 2017;150–153. (In Russ.)].

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2025